Lataa...
Enfortumab Vedotin in urothelial cancer
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor receptor (FGFR) inhibitors and most recently Enf...
Tallennettuna:
| Julkaisussa: | Ther Adv Urol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780177/ https://ncbi.nlm.nih.gov/pubmed/33447264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287220980192 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|